Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (111-120 of 315) with videos related to

Pageof 32
Sort By:
Rapid Communications in Mass Spectrometry : RCM|August 31, 2006
Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of the novel anticancer agent 17-DMAG in human plasmaJavier Moreno-Farre, Yasmin Asad, Simon Pacey, et al.
Current Topics in Medicinal Chemistry|July 18, 2006
Discovery and development of pyrazole-scaffold Hsp90 inhibitorsEdward McDonald, Keith Jones, Paul A Brough, et al.
Journal of Biomolecular Screening|August 7, 2004
High-throughput screening assay for identification of small molecule inhibitors of Aurora2/STK15 kinaseChongbo Sun, Yvette Newbatt, Leon Douglas, et al.
Journal of Biomolecular Screening|November 10, 2006
Identification of novel keratinocyte differentiation modulating compounds by high-throughput screeningMasaru Honma, Mark Stubbs, Ian Collins, et al.
Cell Chemical Biology|June 2, 2021
Evolution of kinase polypharmacology across HSP90 drug discoveryAlbert A Antolin, Paul A Clarke, Ian Collins, et al.
Anticancer Research|August 15, 2002
ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycinVicki Smith, Stephen Hobbs, William Court, et al.
Molecular Cancer Research : MCR|July 30, 2015
Maximizing the Therapeutic Potential of HSP90 InhibitorsLisa M Butler, Roberta Ferraldeschi, Heather K Armstrong, et al.
Cancer Research|February 25, 2010
Drugging the PI3 kinome: from chemical tools to drugs in the clinicPaul Workman, Paul A Clarke, Florence I Raynaud, et al.
Cancer Research|December 3, 2005
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycinSilvy da Rocha Dias, Frank Friedlos, Yvonne Light, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 22, 2003
Validation of liquid chromatography assay for the quantitation of (Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid (SU006668) in human plasma and its application to a phase I clinical trialYasmin Asad, Gillian Cropp, Alison Adams, et al.
Pageof 32

Showing results (111-120 of 315) with videos related to

Sort By:
Pageof 32
Rapid Communications in Mass Spectrometry : RCM|August 31, 2006
Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of the novel anticancer agent 17-DMAG in human plasmaJavier Moreno-Farre, Yasmin Asad, Simon Pacey, et al.
Current Topics in Medicinal Chemistry|July 18, 2006
Discovery and development of pyrazole-scaffold Hsp90 inhibitorsEdward McDonald, Keith Jones, Paul A Brough, et al.
Journal of Biomolecular Screening|August 7, 2004
High-throughput screening assay for identification of small molecule inhibitors of Aurora2/STK15 kinaseChongbo Sun, Yvette Newbatt, Leon Douglas, et al.
Journal of Biomolecular Screening|November 10, 2006
Identification of novel keratinocyte differentiation modulating compounds by high-throughput screeningMasaru Honma, Mark Stubbs, Ian Collins, et al.
Cell Chemical Biology|June 2, 2021
Evolution of kinase polypharmacology across HSP90 drug discoveryAlbert A Antolin, Paul A Clarke, Ian Collins, et al.
Anticancer Research|August 15, 2002
ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycinVicki Smith, Stephen Hobbs, William Court, et al.
Molecular Cancer Research : MCR|July 30, 2015
Maximizing the Therapeutic Potential of HSP90 InhibitorsLisa M Butler, Roberta Ferraldeschi, Heather K Armstrong, et al.
Cancer Research|February 25, 2010
Drugging the PI3 kinome: from chemical tools to drugs in the clinicPaul Workman, Paul A Clarke, Florence I Raynaud, et al.
Cancer Research|December 3, 2005
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycinSilvy da Rocha Dias, Frank Friedlos, Yvonne Light, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 22, 2003
Validation of liquid chromatography assay for the quantitation of (Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid (SU006668) in human plasma and its application to a phase I clinical trialYasmin Asad, Gillian Cropp, Alison Adams, et al.
Pageof 32